友邦推零索偿可取回供款危疾保障产品
友邦香港公布,推出结合危疾、未知严重传染病及终身医疗保障之「智健康」计划,计划分两个阶段执行,第一阶段以一笔过赔偿方式提供涵盖115种疾病的危疾保障,第一阶段保障期满後,零索偿的客户可选择终止保单以取回100%已缴保费,或存入第二阶段的「医疗保障户口」,无须再次核保下转换至实报实销之终身医疗保障。
友邦香港及澳门业务策略及财富管理总经理谢佩兰表示,有关产品有病可获保障,没索偿则可选择取回全数保费,为客户提供两全其美的选择。被问及近月业务回复情况,她指未能披露,重申集团管理层於业绩公告时指,6月疫情舒缓後,业务有回复趋势。现时友邦香港共有28款保险产品可经网上购买。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.